Glaxosmithkline (GSK)

 

Latest News

Broker Forecast - Jefferies International issues a broker note on GlaxoSmithKline PLC

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price ta...

Trelegy Ellipta EU approval for treatment of COPD

RNS Number: 6797W GlaxoSmithKline PLC 16 November 2017 Issued: 16 November 2017, London UK - LSE Announcement Trelegy Ellipta once-daily single inhaler triple therapy gains marketing authorisation in Europe for the treatment of COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Co...

Director/PDMR Shareholding

RNS Number: 2011W GlaxoSmithKline PLC 10 November 2017 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Ms E Walmsley b) Position/status Chief Executive Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market partic...

Block listing Interim Review

RNS Number: 1021W GlaxoSmithKline PLC 09 November 2017 BLOCK LISTING SIX MONTHLY RETURN Information provided on this form must be typed or printed electronically and provided to an ris . Date: 09 November 2017 Name of applicant: GlaxoSmithKline plc Name of scheme: GlaxoSmithKline Share Option Plan - Ordinary Shares Period of return: F...

All News

DateHeadlineSource
16-11-17Broker Forecast - Jefferies International issues a broker note on GlaxoSmithKline PLCStockMarketWire
16-11-17Trelegy Ellipta EU approval for treatment of COPDRNS
10-11-17Director/PDMR ShareholdingRNS
09-11-17Block listing Interim ReviewRNS
09-11-17Time to buy bombed-out Hikma Pharmaceuticals?Interactive Investor
09-11-17Broker Forecast - Societe Generale issues a broker note on GlaxoSmithKline PLCStockMarketWire
08-11-17Board changes at GlaxoSmithKlineStockMarketWire
08-11-17Directorate ChangeRNS
08-11-17Directorate ChangeRNS
08-11-17Broker Forecast - Beaufort Securities issues a broker note on GlaxoSmithKline PLCStockMarketWire
08-11-17How I am preparing for a stockmarket correctionInteractive Investor
07-11-17US regulatory application for mepolizumab in COPDRNS
03-11-17The week ahead: M&S, Halfords, insurersInteractive Investor
02-11-17Broker Forecast - Berenberg issues a broker note on GlaxoSmithKline PLCStockMarketWire
02-11-17Fitch affirms GSK at 'A'StockMarketWire
02-11-17GSK gets breakthrough therapy designation from FDA StockMarketWire
02-11-17BCMA receives FDA Breakthrough Therapy DesignationRNS
01-11-17GlaxoSmithKline, Innoviva see positive results from COPD studyStockMarketWire
01-11-17Total Voting RightsRNS
01-11-17Superiority of Anoro Ellipta demonstrated for COPDRNS
01-11-17Broker Forecast - Kepler Cheuvreux issues a broker note on GlaxoSmithKline PLCStockMarketWire
31-10-17Broker Forecast - Jefferies International issues a broker note on GlaxoSmithKline PLCStockMarketWire
27-10-17Broker Forecast - Barclays Capital issues a broker note on GlaxoSmithKline PLCStockMarketWire
27-10-17Broker Forecast - Deutsche Bank issues a broker note on GlaxoSmithKline PLCStockMarketWire
27-10-17Broker Forecast - JP Morgan Cazenove issues a broker note on GlaxoSmithKline PLCStockMarketWire
26-10-17GSK shingles vaccine recommended by advisory committeeStockMarketWire
25-10-17CDC ACIP makes recommendations for use of ShingrixRNS
25-10-17Director Deals - GlaxoSmithKline PLC (GSK)StockMarketWire
25-10-17Director Deals - GlaxoSmithKline PLC (GSK)StockMarketWire
25-10-17Director Deals - GlaxoSmithKline PLC (GSK)StockMarketWire
25-10-17FTSE falls as weak dollar hits overseas earnersStockMarketWire
25-10-17Director Deals - GlaxoSmithKline PLC (GSK)StockMarketWire
25-10-17Director Deals - GlaxoSmithKline PLC (GSK)StockMarketWire
25-10-17How come GlaxoSmithKline just plunged 6%?Interactive Investor
25-10-17Director/PDMR ShareholdingRNS
25-10-17GSK operating profit, revenue upStockMarketWire
25-10-173rd Quarter ResultsRNS
25-10-17Three funds to play the UKInteractive Investor
23-10-17GSK's Shingrix Receives US FDA ApprovalRNS
20-10-17Director/PDMR ShareholdingRNS

RSS feeds

  • Editorial news feed for LSE:GSK Editorial
  • Regulatory news feed for LSE:GSK Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account